Scandinavian ChemoTech

Regulatory press release

Lund, Sweden 30 January 2025

CEO Mohan Frick commented, "This agreement reflects our commitment to creating a stable foundation for the Company's future growth. Together with our improved revenues and cost-saving measures, the new loans position us to better navigate market challenges and focus on delivering innovative cancer care solutions for both humans and animals."

This announcement comes shortly after ChemoTech's decision to split its business units to enhance cash flow and efficiency, as detailed in its recent communication: Scandinavian ChemoTech Splits Business Units to Boost Cash Flow.

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Certified Adviser: Redeye AB

As of January 9th, 2025, we have discontinued translating our press releases into Swedish. Certain information will still be published in Swedish due to current regulations.

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.